The QCS assay for TROP2 is being implemented more broadly, at the cost of further readout delays.
ApexOnco Front Page
Recent articles
ERAS-0015 data look good, but the company is punished for a pneumonitis death.
But PFS data are lacking, and there are questions about first and second-line plans.
Three private biotechs enter clinical trials, one targeting KRAS.
Early Ibtrozi sales and a low-cost licensing deal with Eisai disappoint investors.
Things look grim for Atara, which had been relying on a milestone from Pierre Fabre.
$650m buys the group rights to RemeGen’s RC148.
The company secures funding to push its lead candidate towards US approval.
